Navigation Links
London Genetics and Astrimmune to Collaborate on Cancer Vaccine

London Genetics and Astrimmune to Collaborate on Cancer Vaccine -- LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Joint Ventures, New Products & Services Click to view news release full screen  

London Genetics and Astrimmune to Collaborate on Cancer Vaccine


LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme. The plan, for Astrimmune's early-stage pancreatic cancer vaccine candidate, will be used in applications for further funding of its development. Financial terms were not disclosed.

Astrimmune's vaccine candidate induces the production of antibodies against gastrin, a hormone which is known to stimulate the growth of many types of gastrointestinal cancer. Since differential response rates have been observed in clinical trials of other gastrin-blocking products, with some patients responding very well and others hardly at all, there is a clear need for biomarkers to help identify those patients most likely to benefit from Astrimmune's product. For example, there is a possibility that the variable response rates may have been due in part to the inclusion of some patients with gastrin-insensitive tumours, or those not able to respond immunologically.

Under the terms of the collaboration, which is supported by a grant from the UK East Midlands Development Agency, London Genetics and Astrimmune will put together a proposal for identification of biomarkers predictive of clinical response. London Genetics' seven academic partners, which have an annual research budget of over GBP650m, are able to provide expertise in areas such as tumour biopsy samples and animal models, as well as expertise in the genetics of immune responses to cancer vaccines.

Dominique Kleyn, CEO of London Genetics, said, 'This collaboration is a significant pharmacogenetics development opportunity, and we are pleased to be working with Astrimmune on this important project. As exemplified by our recent collaboration with Diaceutics and increasingly recognised by the biopharmaceutical industry, pharmacogenetics, biomarkers and patient stratification are becoming an important part of the drug discovery and development process. London Genetics' network of over 3,000 academic groups makes it an ideal partner for pharma and biotech companies in this work.'

Fred Jacobs, Managing Director of Astrimmune, said, 'Pancreatic cancer is an area of serious unmet medical need, with a five-year survival rate of around 5% and few treatment options. Availability of a biomarker to select those patients mostly likely to benefit from Astrimmune's vaccine candidate can be expected to expedite the development of this product and increase its chances of coming to market in the future. London Genetics is an expert in this area and Astrimmune is delighted to be working with the company on this important part of the project development.'

About London Genetics: London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise, based on its access to 3,000 academic groups with a GBP650m annual research spend. Recent deals by London Genetics include a partnership with Diaceutics to accelerate biomarker development in the biopharmaceutical industry. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to

About Astrimmune: Astrimmune (Company Registration: 06379008), is a limited, social enterprise company developing treatments for gastrointestinal cancers. Astrimmune is focussed on the elimination of cancer growth factors that are not yet commercialised and is progressing a new immunogen vaccine candidate for use in gastro-intestinal cancers. The distillation of their prior knowledge, coupled with a research programme to refine patient selection to identify the most responsive patients, provides for an accelerated, low cost development path with an increased chance of successful product registration in the EU and the US. For further information, please go to

For further information please contact: London Genetics Ltd Dominique Kleyn, CEO +44(0)207-594-1838 Emma Palmer Foster, Strategic Communications Consultant +44(0)7880-787185 Astrimmune Fred Jacobs, Managing Director +44(0)7989-386326

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
2. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. First Awards Made by London Genetics Proof-of-Concept Fund
5. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
6. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
7. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
8. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
9. Interleukin Genetics Reports Third Quarter 2010 Financial Results
10. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
11. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  "They really did surround ... her Kaiser Permanente care team, after a routine appointment ... plan for cancer. The 79-year-old Kaiser Permanente Senior Advantage ... went in for what she thought was tendinitis from ... and care team, however, she was diagnosed with and ...
(Date:10/8/2015)... DIEGO , Oct. 8, 2015  Trovagene, ... molecular diagnostics, today announced the presentation of results ... of its Precision Cancer Monitoring SM (PCM) ... be critical for physicians to determine appropriate therapy ... scientific officer of Trovagene is delivering the results ...
(Date:10/8/2015)... York , October 8, 2015 ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 ... valued at USD 2.63 billion in 2013 and is anticipated ... 2022 to reach USD 4.00 billion in 2022. --> ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ...
Breaking Medicine Technology:
... 2011 Eli Lilly and Company (NYSE: ... that supports bold, new education reform, today announced the ... Grow What Works seeks to raise and invest $18 ... enabling them to serve more students and accelerate education ...
... May 4, 2011 Boston Scientific Corporation (NYSE: ... in the adoption of its SpyGlass® Direct Visualization ...  The SpyGlass System guides visualization and accessory devices ... system, including the hepatic ducts.  It was developed ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
(Date:10/9/2015)... , ... October 09, 2015 , ... Santa Rosa Consulting ... partnership as MD Anderson prepares to go-live on the Epic platform in March of ... early 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and ...
(Date:10/9/2015)... ... 2015 , ... Amada Senior Care, premier provider of non-medical ... Maryland – its Bethesda location. Amada franchise partner Steve Schultz came ... consultant to many of the largest construction firms in the Mid-Atlantic region. He ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... franchise, was recognized by Cabarrus County Active Living and Parks for its outstanding ... care company’s dedication to consistently going above and beyond the call of ...
Breaking Medicine News(10 mins):
... Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... chief financial officer, effective March 6, 2009, to pursue other ... Lawrence A. Kenyon, 43, will join Par on December ... the role of chief financial officer on March 9, 2009. ...
... 8, 2008, TooBusyWorking was launched as a next-generation job ... from all major employers onto a single Web site. ... CareerBuilder, HotJobs, and Monster combined. , ... number of job openings, each listing on TooBusyWorking provides ...
... clear before malaria elimination can be achieved. A supplement ... of articles reviewing the many aspects of the research ... supplement,s reviews charts the progress that has been made ... rather than clinical disease prevention. Elimination requires a different ...
... Dec. 12 Terumo Corporation and Terumo,s,subsidiary, Terumo ... into an agreement to settle all outstanding litigation ... number of lawsuits pending,in which each claims the ... all,involve methods and devices used in endoscopic vessel ...
... Labopharm Inc. (TSX: DDS, NASDAQ: DDSS ), at ... Toronto Stock Exchange, today commented on the recent trading ... aware of any reason for the recent trading activity ... (PDUFA) action date for its once-daily formulation of tramadol, ...
... security of online file access from Internet fraud, Vetted International has ... Vetted QuickBase. , ... Raleigh, NC (PRWEB) December xx, ... its online file access from web fraud . An ...
Cached Medicine News:
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Titanium. 0.12 mm 1 x 2 teeth with 7 mm platform. Flat serrated handle with dull finish....
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Medicine Products: